These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 30683770)

  • 21. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
    Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
    Kessel K; Seifert R; Schäfers M; Weckesser M; Schlack K; Boegemann M; Rahbar K
    Theranostics; 2019; 9(17):4841-4848. PubMed ID: 31410185
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
    J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
    Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome and safety of rechallenge [
    Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
    Rosar F; Burgard C; Rohloff LV; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S
    Clin Nucl Med; 2024 Jul; 49(7):621-629. PubMed ID: 38769643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
    Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
    Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Boegemann M; Schrader AJ; Rahbar K
    Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with
    Calais J; Gafita A; Eiber M; Armstrong WR; Gartmann J; Thin P; Nguyen K; Lok V; Gosa L; Grogan T; Esfandiari R; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Ranganathan D; Slavik R; Dahlbom M; Herrmann K; Delpassand E; Fendler WP; Czernin J
    J Nucl Med; 2021 Oct; 62(10):1440-1446. PubMed ID: 34016732
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.